Cancer screening: Benefits, harms and making an informed choice

Australian Family Physician

Volumn 35, Issue 1-2, 2006, Pages 39-42

  Barratt, Alexandra L ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DECISION MAKING; EARLY DIAGNOSIS; HUMAN; LABORATORY DIAGNOSIS; MASS SCREENING; METHODOLOGY; NEOPLASM; PREDICTION AND FORECASTING; RISK ASSESSMENT; RISK FACTOR; STANDARD; TIME;

DECISION MAKING; EARLY DIAGNOSIS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; MASS SCREENING; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 33645520136     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985;14:32-8.
2. Wald NJ. Guidance on terminology. J Med Screen 1994;1:76.
3. Schwartz LM, Woloshin S, Fowler FJ, Welch GH. Enthusiasm for cancer screening in the United States. JAMA 2004;291:71-8.
4. Larson RJ, Woloshin S, Schwartz LM, Welch HG. Celebrity endorsements of cancer screening. J Natl Cancer Inst 2005;97:693-5.
5. Moynihan R. End celebrity endorsement of screening say researchers. BMJ 2005;330:1156.
6. Welch HG, Black WC. Using autopsy series to estimate the disease 'reservoir' for ductal carcinoma in situ of the breast. Ann Intern Med 1997;127:1023-8.
7. Barratt A, Howard K, Irwig L, Salkeld G, Houssami N. Model of outcomes of screening mammography; information to support informed choices. BMJ 2005;330:936-8.
8. Barratt A, Irwig L, Glasziou P, et al. Users' guides to the medical literature XVII. How to use guidelines and recommendations about screening. JAMA 1999;281:2029-34.
9. Morrison AS. Screening in chronic disease. 2nd ed. New York: Oxford University Press, 1992.
10. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78.
11. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson IC. Incidence and treatment for ductal carcinoma in situ of the breast. JAMA 1996;275:913-8.
12. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography J Natl Cancer Inst 2002;94:1546-54.
13. Paci E, Duffy SW. Overdiagnosis and overtreatment in service screening. Breast Cancer Research 2005;7:266-70.
14. Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 2004;328:921-4.
15. Kerlikowske K, Grady D, Rubin SH, Sandrock C, Ernster VL. Efficacy of screening mammography: a meta-analysis. JAMA 1995;273:149-54.
16. Glasziou P. Meta-analysis adjusting for compliance: the example of screening for breast cancer. J Clin Epidemiol 1992;45:1251-6.
17. Robinson MHE, Hardcastle JD, Moss SM, et al. The risks of screening: data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer. Gut 1999;45:588-92.
18. Available at www.ahrq.gov/clinic/uspstf/uspscolo.htm
19. Available at www.ahrq.gov/clinic/uspstfix.htm.
20. O'Connor AM, Rostom A, Fiset V, et al. Decision aids for patients facing health treatment or screening decisions: a systematic review. BMJ 1999;319:731-4.